• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Carboxylic acid derivatives Carboxylic acid amides

Research Briefing on 4-Amino-1-ethyl-N-(3-pyrazol-1-ylpropyl)pyrazole-3-carboxamide;hydrochloride (CAS: 1431963-40-4)

The compound 4-Amino-1-ethyl-N-(3-pyrazol-1-ylpropyl)pyrazole-3-carboxamide;hydrochloride (CAS: 1431963-40-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This small molecule, characterized by its pyrazole and carboxamide functional groups, has shown promising potential in various therapeutic applications, particularly in the modulation of protein-protein interactions and enzyme inhibition. Recent studies have explored its pharmacokinetic properties, mechanism of action, and potential clinical applications, making it a compound of high interest for drug development.

One of the key areas of research involving this compound is its role as a selective inhibitor of specific kinase pathways. Kinases are critical regulators of cellular signaling, and their dysregulation is often implicated in diseases such as cancer, inflammatory disorders, and neurodegenerative conditions. Preliminary in vitro studies have demonstrated that 4-Amino-1-ethyl-N-(3-pyrazol-1-ylpropyl)pyrazole-3-carboxamide;hydrochloride exhibits high affinity and selectivity for certain kinase targets, suggesting its potential as a lead compound for the development of novel therapeutics. Further investigations are underway to elucidate its exact binding mode and downstream effects.

In addition to its kinase inhibitory activity, recent research has also highlighted the compound's potential in targeting G-protein-coupled receptors (GPCRs). GPCRs represent one of the largest families of drug targets, and the ability of this compound to interact with specific GPCR subtypes opens new avenues for therapeutic intervention. Studies using high-throughput screening and molecular docking simulations have provided insights into its binding affinity and selectivity profiles, which are crucial for optimizing its pharmacological properties.

The pharmacokinetic profile of 4-Amino-1-ethyl-N-(3-pyrazol-1-ylpropyl)pyrazole-3-carboxamide;hydrochloride has also been a focus of recent investigations. Early-stage preclinical studies have evaluated its absorption, distribution, metabolism, and excretion (ADME) properties, as well as its bioavailability and stability under physiological conditions. These studies are essential for determining the compound's suitability for further development and its potential to progress to clinical trials. Initial results indicate favorable pharmacokinetic characteristics, though additional optimization may be required to enhance its therapeutic efficacy and reduce potential off-target effects.

Another notable aspect of this compound is its application in combination therapies. Researchers have explored its synergistic effects when used alongside other therapeutic agents, particularly in the context of cancer treatment. For instance, combining this compound with conventional chemotherapeutic drugs has shown enhanced efficacy in inhibiting tumor growth in animal models. These findings underscore the potential of 4-Amino-1-ethyl-N-(3-pyrazol-1-ylpropyl)pyrazole-3-carboxamide;hydrochloride as part of a multi-targeted approach to disease treatment.

Despite the promising results, challenges remain in the development of this compound. Issues such as solubility, metabolic stability, and potential toxicity need to be addressed to ensure its clinical viability. Ongoing research is focused on structural modifications and formulation strategies to overcome these hurdles. Additionally, the compound's mechanism of action in vivo and its long-term safety profile require further investigation to fully understand its therapeutic potential.

In conclusion, 4-Amino-1-ethyl-N-(3-pyrazol-1-ylpropyl)pyrazole-3-carboxamide;hydrochloride (CAS: 1431963-40-4) represents a promising candidate for drug development, with demonstrated activity in kinase inhibition and GPCR modulation. Its favorable pharmacokinetic properties and potential for combination therapies further enhance its appeal as a therapeutic agent. However, continued research is necessary to address existing challenges and fully realize its clinical potential. This compound exemplifies the innovative approaches being pursued in chemical biology and pharmaceutical research to develop next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)